Targeting cell surface receptors offers key advantages, including the ability to disrupt dysregulated pathways driven by oncoproteins such as EGFR, HER2, VEGFR, and PD-PDL1, which are essential for cancer cell growth and survival [1,2,3,4,5]. This evidence concerns the gene ERBB2 and cancer.